trending Market Intelligence /marketintelligence/en/news-insights/trending/vafsq5azxafhpiyrqmtj0q2 content esgSubNav
In This List

Compugen plans $21M direct offering of ordinary shares, warrants

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Compugen plans $21M direct offering of ordinary shares, warrants

Compugen Ltd. plans to raise gross proceeds to about $21 million through a registered direct offering of shares and warrants.

The Israel-based company will issue about 5.3 million ordinary shares at $3.95 apiece to certain institutional investors.

Compugen also plans to issue warrants to buy up to 4.3 million additional ordinary shares.

The warrants may be exercised at $4.74 per share and will be exercisable six months following issuance and have a term of five years from date of issue.

The offering is expected to close on or about June 19.

Net proceeds will be used to fund preclinical and clinical development of the company's product candidates and for other general corporate purposes.

JMP Securities LLC is acting as exclusive placement agent for the offering.

Compugen uses its predictive discovery infrastructure to identify drug targets and develop therapeutics in the field of cancer immunotherapy.